Mylan Inc (MYL) Gets a Buy Rating from Credit Suisse

Credit Suisse analyst Lorenzo Biasio maintained a Buy rating on Mylan Inc (MYLResearch Report) yesterday and set a price target of $33. The company’s shares opened today at $21.80, close to its 52-week low of $21.23.

According to TipRanks.com, Biasio is a 3-star analyst with an average return of 4.0% and a 60.8% success rate. Biasio covers the Healthcare sector, focusing on stocks such as Coherus Biosciences, Thermo Fisher, and Illumina.

Mylan Inc has an analyst consensus of Moderate Buy, with a price target consensus of $31.08, representing a 42.6% upside. In a report released yesterday, Raymond James also maintained a Buy rating on the stock with a $31 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $42.50 and a one-year low of $21.23. Currently, Mylan Inc has an average volume of 6.43M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World.